Biomet is the manufacturer of the M2a Magnum Hip System, a metal-on-metal hip replacement device that was marketed as a superior artificial joint to people with degenerative hips. Like most of the all-metal hips that were introduced, the M2a Magnum proved problematic soon after it was implanted in thousands of recipients. Thousands of lawsuits have been filed by M2a Magnum recipients, alleging injuries caused by early failure of the device, necessitating revision surgery to remove and replace the faulty implant. Many plaintiffs have suffered permanent loss of mobility, and other serious injuries, leading them to seek compensation for medical expenses, loss of income, and other damages.
Has the Biomet M2a Magnum Hip System Been Recalled?
The Biomet M2a Magnum hip is very similar to the DePuy Orthopaedics ASR hip replacement implant, which was recalled in August 2010. Biomet has not issued a recall of its device, but many orthopedic surgeons will no longer use it or other all-metal hip devices still on the market, when performing hip replacement surgery.
Biomet Multidistrict Litigation
In October 2012, the U.S. Judicial Panel on Multidistrict Litigation (JPML) approved the transfer of pending federal Biomet M2a Magnum Hip System lawsuits to the U.S. District Court for the District of Northern Indiana, consolidating them into a multidistrict litigation (MDL). The consolidation is allowing pretrial proceedings in all Biomet lawsuits to be overseen by one judge, speeding up the process. The lawsuits, however, will go to trial or settle out-of-court individually. MDLs are common when a large number of plaintiffs file personal injury lawsuits against one defendant.
Biomet Jury Awards and Settlements
At present, there has not been any compensation awarded to Biomet plaintiffs by juries, nor has there been word of Biomet settling out-of-court with any plaintiffs. Typically, personal injury lawsuits take about two years to reach the trial phase of litigation after they are filed. As the number of M2a Magnum Hip System plaintiffs increases, Biomet might consider an attempt at settling with some of them, but so far, there has not been any announcement of a settlement offer from the embattled manufacturer.